3
Announcements
Trials
Browse
Landscape
Status
Completed
31
Recruiting
29
Active not recruiting
15
Terminated
11
Withdrawn
1
Not yet recruiting
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1
Interventions
tempol
2
balstilimab
2
zolbetuximab
1
zipalertinib
1
venetoclax
1
ulixertinib
1
tisagenlecleucel
1
tipifarnib
1
tebentafusp
1
talazoparib
1
sodium thiosulfate
1
selinexor
1
ruxolitinib
1
ribociclib
1
osunprotafib
1
nirogacestat
1
mirdametinib
1
lifileucel
1
leronlimab
1
idecabtagene vicleucel
1
gedatolisib
1
ensartinib
1
dodecyl maltoside
1
burosumab
1
brexucabtagene autoleucel
1
belantamab mafodotin
1
axicabtagene ciloleucel
1
asciminib
1
anlotinib
1
TEMPOL-H
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
INDUSTRY
×
ribociclib
×
Clear all
NCT05038631
2026-04-13
Managed Access Programs for LEE011, Ribociclib
Novartis
Available